{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:30:42Z","timestamp":1773333042313,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12094-019-02113-y","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T08:03:47Z","timestamp":1555661027000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Unveiling the mechanisms of immune evasion in pancreatic cancer: may it be a systemic inflammation responsible for dismal survival?"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-7602","authenticated-orcid":false,"given":"K.","family":"Holub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Conill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"2113_CR1","unstructured":"National Cancer Institute: SEER Stat Fact Sheets: Pancreatic Cancer. \nhttp:\/\/seer.cancer.gov\/statfacts\/html\/corp.html\n\n. Accessed 28 Dec 2018."},{"key":"2113_CR2","unstructured":"European Cancer Information System: Data Explorer \nhttps:\/\/ecis.jrc.ec.europa.eu\/explorer.php\n\n Accessed 9 Jan 2019."},{"key":"2113_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1809775\n\n.","journal-title":"N Engl J Med"},{"issue":"5","key":"2113_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Go\u00e9r\u00e9 D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015;26(5):56\u201368. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdv295\n\n(e-update\u2014cancer of the pancreas treatment recommendations. Published: 15 March 2019. Authors: ESMO Guidelines Committee).","journal-title":"Annals of Oncology"},{"issue":"1","key":"2113_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers10010006","volume":"10","author":"N Martinez-Bosch","year":"2018","unstructured":"Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy. Cancers. 2018;10(1):1\u20136. \nhttps:\/\/doi.org\/10.3390\/cancers10010006\n\n.","journal-title":"Cancers"},{"key":"2113_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218\u201330. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010\n\n.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2113_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2018.09.016","volume":"132","author":"RD Dolan","year":"2018","unstructured":"Dolan RD, Laird BJA, Horgan PG, McMillan DC. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: a systematic review. Crit Rev Oncol Hematol. 2018;132:130\u20137. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2018.09.016\n\n.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2113_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/bjc.2013.332","volume":"109","author":"M Stotz","year":"2013","unstructured":"Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, Stojakovic T, Samonigg H, Hoefler G, Pichler M. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109:416\u201321.","journal-title":"Br J Cancer"},{"issue":"3","key":"2113_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.pan.2015.10.006","volume":"16","author":"T Asaoka","year":"2016","unstructured":"Asaoka T, Miyamoto A, Maeda S, Tsujie M, Hama N, Yamamoto K, Miyake M, Haraguchi N, Nishikawa K, Hirao M, Ikeda M, Sekimoto M, Nakamori S. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016;16(3):434\u201340. \nhttps:\/\/doi.org\/10.1016\/j.pan.2015.10.006\n\n.","journal-title":"Pancreatology"},{"key":"2113_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00595-015-1206-3","volume":"46","author":"S Asari","year":"2016","unstructured":"Asari S, Matsumoto I, Toyama H, Shinzeki M, Goto T, Ishida J, Ajiki T, Fukumoto T, Ku Y. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today. 2016;46:583\u201392.","journal-title":"Surg Today"},{"key":"2113_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/CBM-160645","volume":"17","author":"V Formica","year":"2016","unstructured":"Formica V, Morelli C, Ferroni P, Nardecchia A, Tesauro M, Pelicori S, Cereda V, Russo A, Riondino S, Guadagni F, Roselli M. Neutrophil\/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Cancer Biomark. 2016;17:335\u201345.","journal-title":"Cancer Biomark"},{"key":"2113_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1245\/s10434-016-5634-0","volume":"24","author":"M Sierzega","year":"2017","unstructured":"Sierzega M, Lenart M, Rutkowska M, Surman M, Mytar B, Mataja A, Siedlar M, Kulig J. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol. 2017;24:808\u201315. \nhttps:\/\/doi.org\/10.1245\/s10434-016-5634-0\n\n.","journal-title":"Ann Surg Oncol"},{"key":"2113_CR13","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.2147\/CMAR.S173444","volume":"10","author":"S Ye","year":"2018","unstructured":"Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2018;10:3405\u201317. \nhttps:\/\/doi.org\/10.2147\/CMAR.S173444\n\n.","journal-title":"Cancer Manag Res"},{"key":"2113_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2018.01.024","volume":"479","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing 8252 patients. Clin Chim Acta. 2018;479:181\u20139. \nhttps:\/\/doi.org\/10.1016\/j.cca.2018.01.024\n\n.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2113_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.hpb.2017.12.009","volume":"20","author":"NG Mowbray","year":"2018","unstructured":"Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B. A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford). 2018;20(5):379\u201384. \nhttps:\/\/doi.org\/10.1016\/j.hpb.2017.12.009\n\n.","journal-title":"HPB (Oxford)"},{"issue":"3","key":"2113_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14701\/ahbps.2018.22.3.197","volume":"22","author":"A Giakoustidis","year":"2018","unstructured":"Giakoustidis A, Neofytou K, Costa Neves M, Giakoustidis D, Louri E, Cunningham D, Mudan S. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg. 2018;22(3):197\u2013207. \nhttps:\/\/doi.org\/10.14701\/ahbps.2018.22.3.197\n\n.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"issue":"5","key":"2113_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1600-0609.1987.tb01457.x","volume":"39","author":"J Hirata","year":"1987","unstructured":"Hirata J, Koga T, Nishimura J, Ibayashi H. Pancreatic carcinoma associated with marked eosinophilia: a case report. Eur J Haematol. 1987;39(5):462\u20136 (PubMed: 3500871).","journal-title":"Eur J Haematol"},{"issue":"5","key":"2113_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1155\/2006\/386918","volume":"20","author":"A Cay","year":"2006","unstructured":"Cay A, Imamoglu M, Cobanoglu U. Eosinophilic pancreatitis mimicking pancreatic neoplasia. Can J Gastroenterol. 2006;20(5):361\u20134 (PubMed: 16691304).","journal-title":"Can J Gastroenterol"},{"key":"2113_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1590\/S0074-02761997000800023","volume":"92","author":"PF Weller","year":"1997","unstructured":"Weller PF, Lim K. Human eosinophil-lymphocyte interactions. Mem Inst Oswaldo Cruz Rio de Janeiro. 1997;92:173\u201382.","journal-title":"Mem Inst Oswaldo Cruz Rio de Janeiro"},{"key":"2113_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.trecan.2016.10.002","volume":"2","author":"H Reichman","year":"2016","unstructured":"Reichman H, Karo-Atar D, Munitz A. Emerging roles for eosinophils in the tumour microenvironment. Trends Cancer. 2016;2:664\u201375.","journal-title":"Trends Cancer"},{"issue":"1","key":"2113_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15226\/2374-815X\/5\/1\/001109","volume":"5","author":"M Manohar","year":"2017","unstructured":"Manohar M, Verma AK, Venkateshaiah SU, Mishra A. Significance of eosinophils in promoting pancreatic malignancy. J Gastroenterol Pancreatol Liver Disord. 2017;5(1):1\u201315. \nhttps:\/\/doi.org\/10.15226\/2374-815X\/5\/1\/001109\n\n.","journal-title":"J Gastroenterol Pancreatol Liver Disord"},{"issue":"2","key":"2113_CR22","doi-asserted-by":"publisher","first-page":"e1393134","DOI":"10.1080\/2162402x.2017.1393134","volume":"7","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2017;7(2):e1393134. \nhttps:\/\/doi.org\/10.1080\/2162402x.2017.1393134\n\neCollection 2018.","journal-title":"Oncoimmunology"},{"key":"2113_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2174\/0929867323666160119094313","volume":"23","author":"S Sakkal","year":"2016","unstructured":"Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavorable? Curr Med Chem. 2016;23:650\u201366.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2113_CR24","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1186\/s12885-018-5131-x","volume":"18","author":"K Holub","year":"2018","unstructured":"Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer. 2018;18(1):1280. \nhttps:\/\/doi.org\/10.1186\/s12885-018-5131-x\n\n.","journal-title":"BMC Cancer"},{"issue":"7","key":"2113_CR25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s12094-018-1991-4","volume":"21","author":"K. Holub","year":"2018","unstructured":"Holub K, Biete A (2018) Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients. Clin Transl Oncol. \nhttps:\/\/doi.org\/10.1007\/s12094-018-1991-4\n\n.","journal-title":"Clinical and Translational Oncology"},{"key":"2113_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00423-010-0622-5","volume":"395","author":"AL Mihaljevic","year":"2010","unstructured":"Mihaljevic AL, Michalski CW, Friess H, et al. Molecular mechanism of pancreatic cancer\u2014understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg. 2010;395:295. \nhttps:\/\/doi.org\/10.1007\/s00423-010-0622-5\n\n.","journal-title":"Langenbecks Arch Surg"},{"key":"2113_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/bjc.2013.32","volume":"108","author":"Y Ino","year":"2013","unstructured":"Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108:914\u201323.","journal-title":"Br J Cancer"},{"key":"2113_CR28","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1038\/onc.2013.257","volume":"33","author":"SM W\u00f6rmann","year":"2013","unstructured":"W\u00f6rmann SM, Diakopoulos KN, Lesina M, Alg\u00fcl H. The immune network in pancreatic cancer development and progression. Oncogene. 2013;33:2956. \nhttps:\/\/doi.org\/10.1038\/onc.2013.257\n\n.","journal-title":"Oncogene"},{"issue":"1","key":"2113_CR29","doi-asserted-by":"publisher","first-page":"10566","DOI":"10.1038\/s41598-018-28646-w","volume":"8","author":"J Fest","year":"2018","unstructured":"Fest J, Ruiter R, Ikram M, et al. Reference values for white blood-cell-based inflammatory markers in the Rotterdam Study: a population-based prospective cohort study. Sci Rep. 2018;8(1):10566. \nhttps:\/\/doi.org\/10.1038\/s41598-018-28646-w\n\n.","journal-title":"Sci Rep"},{"issue":"12","key":"2113_CR30","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"Budczies","year":"2012","unstructured":"Budczies, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization (2012). PLoS One. 2012;7(12):e51862.","journal-title":"PLoS One"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02113-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02113-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T23:20:53Z","timestamp":1587165653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02113-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2113"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02113-y","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The datasets used and\/or analysed during the current study are available on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"No potential conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study was approved by the Ethical Committee of the Hospital Clinic de Barcelona.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients included in the study signed the informed consent for treatment, data processing and publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}